Status:
COMPLETED
Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in North America. The aim of this trial is asses the long term safety and efficacy of biphasic insulin aspart 30 in Canadian subjects with type 2 diabetes who had participated ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Completed the BIAsp-1237 trial
Exclusion
Key Trial Info
Start Date :
November 23 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 12 2004
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT01527539
Start Date
November 23 2001
End Date
October 12 2004
Last Update
February 24 2017
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Halifax, Nova Scotia, Canada, B3H 1V7
2
Novo Nordisk Investigational Site
Toronto, Ontario, Canada, M5B 1W8
3
Novo Nordisk Investigational Site
Edmonton, Canada, T5H 3V9
4
Novo Nordisk Investigational Site
Windsor, Canada, N8W 3K2